CYTK - Cytokinetics, Incorporated
| Previous Close | 7.61 |
| Open | 7.61 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 7.31 - 7.75 |
| 52 Week Range | 6.21 - 15.65 |
| Volume | 140,189 |
| Avg. Volume | 266,644 |
| Market Cap | 416.265M |
| Beta (3Y Monthly) | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings Date | Nov 1, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.83 |
- GlobeNewswire•7 days ago
Report: Developing Opportunities within Denny's, Cytokinetics, Beazer Homes, Heidrick & Struggles International, Equity Commonwealth, and Spok — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•8 days ago
The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
- GlobeNewswire•11 days ago
Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program
Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions. In addition to reldesemtiv, the companies are advancing another fast skeletal muscle troponin activator (FSTA) into Investigational New Drug (IND)-enabling studies and continuing their joint research program through 2019. Cytokinetics has been developing reldesemtiv as a potential treatment for people with Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and other debilitating neuromuscular diseases and conditions associated with skeletal muscle weakness and/or fatigue.
- GlobeNewswire•13 days ago
Cytokinetics to Host R&D Day on October 16, 2018
Cytokinetics, Incorporated (CYTK), today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City. Members of Cytokinetics’ senior management will be joined by expert clinicians to provide new updates to the pipeline and review current clinical programs.
- Simply Wall St.•15 days ago
Cytokinetics Incorporated (NASDAQ:CYTK): Risks You Need To Consider Before Buying
If you’re interested in Cytokinetics Incorporated (NASDAQ:CYTK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
- GlobeNewswire•20 days ago
Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald ...
- Benzinga•24 days ago
Cantor Fitzgerald's 7 Buys For 7 Biotechs
Cantor Fitzgerald has high hopes for patients with rare and orphan diseases. “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...
- Benzinga•29 days ago
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
- GlobeNewswire•last month
Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference
Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 11:40 AM ET at the Grant Hyatt in New York City. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
- GlobeNewswire•2 months ago
Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter
Cytokinetics, Incorporated (CYTK) today announced that The ALS Association Golden West Chapter is the inaugural recipient of the Cytokinetics Communications Fellowship, an annual grant from the company intended to support increased capacity and community engagement for nonprofit organizations. “As a longstanding partner of the disease and patient advocacy community, we recognized a need for organizations to expand the scope of their communications to support families with rare diseases of muscle dysfunction and we sought an opportunity to close that gap,” said Diane Weiser, Cytokinetics’ Vice President of Corporate Communications and Investor Relations. “We are extremely grateful to Cytokinetics and honored to receive this unique grant,” said Fred Fisher, MSW, President and CEO of The ALS Association Golden West Chapter.
- Benzinga•2 months ago
Cytokinetics Downgraded On Data Delay
Biopharma Cytokinetics Inc. (NASDAQ: CYTK ) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley. The Analysts Morgan Stanley's Matthew Harrison ...
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in US Foods Holding, Limelight Networks, Ladenburg Thalmann Financial Services, MPLX LP, Cytokinetics, and FuelCell Energy — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CYTK earnings conference call or presentation 26-Jul-18 8:30pm GMT
Q2 2018 Cytokinetics Inc Earnings Call
- Associated Press•3 months ago
Cytokinetics: 2Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 51 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•3 months ago
Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results
Phase 2 Study of Reldesemtiv in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure. Results from Phase 2 Clinical Trial of Reldesemtiv ...
- SmarterAnalyst•4 months ago
3 Biotechs with Upcoming Data to Watch
Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.
- Simply Wall St.•4 months ago
June Best Growth Stocks
Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Globant and Cytokinetics are considered to be high growth in terms of howRead More...
- Zacks•4 months ago
Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
